全文获取类型
收费全文 | 3244篇 |
免费 | 193篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 71篇 |
妇产科学 | 84篇 |
基础医学 | 599篇 |
口腔科学 | 110篇 |
临床医学 | 285篇 |
内科学 | 707篇 |
皮肤病学 | 47篇 |
神经病学 | 331篇 |
特种医学 | 101篇 |
外科学 | 188篇 |
综合类 | 28篇 |
一般理论 | 1篇 |
预防医学 | 244篇 |
眼科学 | 58篇 |
药学 | 304篇 |
中国医学 | 20篇 |
肿瘤学 | 257篇 |
出版年
2024年 | 4篇 |
2023年 | 28篇 |
2022年 | 117篇 |
2021年 | 183篇 |
2020年 | 94篇 |
2019年 | 114篇 |
2018年 | 112篇 |
2017年 | 78篇 |
2016年 | 119篇 |
2015年 | 110篇 |
2014年 | 169篇 |
2013年 | 192篇 |
2012年 | 285篇 |
2011年 | 315篇 |
2010年 | 164篇 |
2009年 | 101篇 |
2008年 | 224篇 |
2007年 | 194篇 |
2006年 | 203篇 |
2005年 | 162篇 |
2004年 | 141篇 |
2003年 | 115篇 |
2002年 | 104篇 |
2001年 | 13篇 |
2000年 | 5篇 |
1999年 | 5篇 |
1998年 | 9篇 |
1997年 | 8篇 |
1996年 | 4篇 |
1995年 | 7篇 |
1994年 | 9篇 |
1993年 | 4篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 3篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 6篇 |
1974年 | 2篇 |
1973年 | 4篇 |
1972年 | 4篇 |
1970年 | 3篇 |
排序方式: 共有3456条查询结果,搜索用时 31 毫秒
41.
Rissanen TT Korpisalo P Markkanen JE Liimatainen T Ordén MR Kholová I de Goede A Heikura T Gröhn OH Ylä-Herttuala S 《Circulation》2005,112(25):3937-3946
42.
Dunić I Djurković-Djaković O Vesić S Zerjav S Jevtović D 《International journal of STD & AIDS》2005,16(7):475-478
A prospective study to evaluate the incidence of herpes zoster (HZ) as an immune restoration disease in patients with AIDS during highly active antiretroviral therapy (HAART) was conducted in a series of 115 patients diagnosed with AIDS initiated on HAART between 1 January 2000 and 31 July 2001. Of these, a single dermatomal HZ episode occurred in 14 (12%) patients within one and 15 months of HAART (median eight months). The HZ patients were similar to the non-HZ patients in age, sex, and HIV transmission risk factor, but had a more advanced disease. Compared with the baseline values, the viral loads significantly (P<0.01) decreased, while the mean CD4+ T-cell counts increased by almost four-fold (P<0.01) in both groups at the time of the HZ episode (or equivalent in non-HZ), but remained below 400/mL in the HZ patients. HZ during HAART is an immunopathological consequence of the improvement of the host immuneresponse, correlating with the beginning of immune restoration. 相似文献
43.
Rodríguez-Nóvoa S Morello J Barreiro P Maida I García-Gascó P Vispo E González-Pardo G Parra A Jiménez-Nácher I Soriano V 《AIDS research and human retroviruses》2008,24(6):821-825
Plasma concentration of atazanavir (ATV) may be reduced when coadministered with tenofovir (TDF) or proton pump inhibitors. Boosting ATV exposure with ritonavir (r) may make it possible to overcome these drug interactions. However, jaundice and loss of the metabolic advantages of ATV are more frequent using ATV/r than ATV alone. Herein, we assessed whether therapeutic drug monitoring (TDM) could make it possible to identify the subset of patients in whom removal of ritonavir could be attempted without risk of suboptimal plasma ATV exposure and subsequent virological failure. A total of 56 patients with undetectable plasma HIV-RNA under a stable triple regimen containing ATV 300/100 mg qd were switched to ATV 400 mg qd. Plasma ATV concentrations were measured using a reliable high-performance liquid chromatography method. Median plasma ATV C(min) fell from 880 to 283 ng/ml (p = 0.03) after removal of ritonavir. While all patients on ATV/r showed ATV plasma concentrations within therapeutic values (IC(min) above 150 ng/ml) before switching, four patients (7%) fell below this threshold after switching to ATV 400 mg qd. However, only one of this group experienced virological failure at week 24 of follow-up. TDF was part of the antiretroviral regimen in all four cases. From a total of 29 (52%) patients on ATV/r showing grade 3-4 hyperbilirubinemia, only 7 (12%) remained on it upon switching to ATV 400 mg qd (p < 0.001). Patients with complete viral suppression under ATV/r 300/100 mg qd may benefit from switching to ATV 400 mg qd guided by TDM, which may make it possible to minimize adverse events without compromising antiviral efficacy in most cases. 相似文献
44.
Maria T. Rinaudo Magda Curto Ivana Rabbone Marco Piccinini Renato Bruno Silvia Mioletti Silvia Gamba 《Journal of diabetes and its complications》1994,8(4):221-225
In circulating lymphocytes from patients with non-insulin-dependent diabetes mellitus (NIDDM) subnormal pyruvate dehydrogenase (PDH) activity returns to normal following patient treatment with sulfonylurea (gliclazide*, 80 mg twice daily/5 weeks). Moreover, in vitro in cells from diabetic patients exposed to insulin at 50 μU/mL PDH activation also occurs; in cells of controls the same happens for insulin at 5 μU/mL, whereas at 50 μU/mL inhibition takes place. Therefore, the low PDH activity in cells of NIDDM patients might be caused by defective insulin control on the enzyme and its recovery in gliclazide-treated patients by drug-mediated removal of the defect. The validity of the hypothesis was verified in this study where cells of NIDDM patients before and after gliclazide treatment were exposed, in vitro, to insulin at 5 and 50 μU/mL and then tested for PDH activity. In such conditions, the profile of PDH behavior in treated patients was no longer comparable to that in untreated patients but closer to that in euglycemic controls, thus supporting the view that the recovery of PDH activity in NIDDM patients following gliclazide treatment might be the expression of an additional effect that the drug would have in these patients, aimed to renew cell responsiveness to insulin. 相似文献
45.
46.
47.
Dana P. Turner Adriana D. Lebowitz Ivana Chtay Timothy T. Houle 《Current pain and headache reports》2018,22(9):62
Purpose of Review
This review synthesizes the utility of measuring migraine triggers for the purpose of forecasting future headache attacks. The nature of forecasting models, headache triggers as inputs to such models, and how these trigger exposures can be measured for forecasting are reviewed. A critical evaluation of the existing forecasting models in the context of their potential application for preemptive treatment is considered.Recent Findings
A substantial pool of candidate trigger factors could be considered in the creation of forecasting models. However, because mechanistic information about causal factors that precede a migraine attack is not well understood, and such factors are difficult to measure, empirical models that are based on trigger factors that are merely associated with the onset of headache activity are likely to be the focus of forecasting efforts in the near future. Of such factors, stress has considerable empirical support and has been used to successfully forecast future headache attacks within individuals over time. However, at present, existing models possess only modest levels of discrimination and lack strong resolution in generated predictions.Summary
Current headache forecasting models represent an important first step in accurately predicting future headache activity. However, to utilize these models in a preemptive treatment paradigm where the risk of headache is treated prior to the actual experience of pain, these models must achieve greater precision with good calibration and generate predictions that are clinically actionable by individuals in their real-time home environments.48.
49.
50.
Costa LJ Feldman AL Micallef IN Inwards DJ Johnston PB Porrata LF Ansell SM 《British journal of haematology》2008,142(3):404-412
Patients with germinal center B cell-like (GCB) and non-GCB diffuse large B cell lymphomas (DLBCL) receiving first line therapy have distinct prognosis. We explored the differences in outcome following salvage autologous hematopoietic stem cell (HSC) transplantation between patients with GCB and non-GCB DLBCL. Forty-four patients with relapsed and 15 patients with primary refractory chemosensitive disease undergoing BEAM (BCNU [carmustine], etoposide, cytarabine, melphalan) conditioning and autologous HSC were included. Immunohistochemical analysis was performed for CD10, BCL-6, MUM1 (allowing classification into GCB and non-GCB-like DLBCL) and BCL-2. Median follow-up of survivors was 25 months; median age at the time of transplantation was 60 years (range 17–77). Thirty-two patients (54%) were classified as having GCB and 27 (46%) as having non-GCB-like DLBCL. Patients with GCB and non-GCB DLBCL did not differ in the risk of progression after HSC transplant ( P = 0·78) or overall survival ( P = 0·48). In multivariate analysis, only time to progression after initial treatment impacted overall survival. We conclude that patients with relapsed or primary refractory chemosensitive GCB and non-GCB-like DLBCL derive similar benefit from autologous HSC transplant. 相似文献